The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris
Huberman Lab Podcast Recap
Published:
Duration: 2 hr 53 min
Guests: Dr. Robin Carhart-Harris
Summary
Dr. Robin Carhart-Harris discusses the potential of psychedelics like psilocybin in treating mental health disorders. The episode highlights the promising results from clinical trials and ongoing research into the neural mechanisms involved.
What Happened
Dr. Robin Carhart-Harris, a Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco, explains how psychedelics like psilocybin can alter neural circuitry in the brain. His research shows that psychedelics primarily work on the serotonin 2A receptor, leading to profound changes in brain connectivity and potential therapeutic effects.
Clinical trials have demonstrated that psilocybin can alleviate symptoms of major depression in over 67% of individuals who undergo treatment. Typical therapeutic sessions involve a 25mg dose of psilocybin, with patients often experiencing significant relief from depressive symptoms, sometimes more effectively than traditional antidepressants.
The episode also addresses the phenomenon of increased brain connectivity under the influence of psychedelics. This connectivity is correlated with the magnitude of subjective effects, suggesting a possible link between neural and experiential changes.
Dr. Carhart-Harris discusses the integration phase post-psychedelic therapy, which is crucial for consolidating insights and maximizing neuroplasticity. The integration work is likened to practices such as meditation, which can help maintain therapeutic benefits over the long term.
Microdosing, involving sub-perceptible doses of psychedelics, is mentioned but lacks compelling evidence for its efficacy. A study highlighted in the episode found that the placebo effect was as strong as the effects of microdosing, casting doubt on its therapeutic value.
The episode mentions ongoing research and trials, including the use of psychedelics for treating conditions like anorexia and fibromyalgia, both showing promising preliminary results. Psilocybin therapy for anorexia has led to improvements in weight and reduced obsessive thoughts about food.
Dr. Carhart-Harris also touches on the legal landscape of psychedelics, noting that despite some decriminalization efforts, full legality remains a complex issue. The FDA is moving towards licensing psychedelics as medicines, with phase three trials underway to ensure their efficacy and safety.
Finally, the concept of non-hallucinogenic psychedelics is explored. Some researchers aim to develop drugs that mimic the therapeutic effects of psychedelics without the hallucinatory experience, though there is skepticism about whether the therapeutic actions can be separated from the psychedelic effects.
Key Insights
- Psilocybin can alleviate symptoms of major depression in more than 67% of people in clinical trials, offering a higher success rate than typical antidepressants.
- Psychedelics work on the serotonin 2A receptor, leading to increased interconnectivity in brain regions, which correlates with therapeutic outcomes.
- Microdosing lacks compelling evidence for therapeutic benefits, with studies showing the placebo effect can be as strong as the perceived effects of microdosing.
- The integration phase after psychedelic therapy is crucial for lasting benefits, similar to how meditation can help maintain mindfulness and presence.